The proposed mechanism for BVZ‐induced HTN, a well‐known side‐effect of the drug, is increased vascular resistance due to the inhibition of vasodilation mediated by vascular endothelial growth factor. The gene discussed is VEGFA; the disease is hypertensive disorder.